Is my patient right for Pod Therapy?

Who is appropriate for the Omnipod DASH® Insulin Pump System?

The Omnipod DASH® Insulin Pump System is intended for continuous subcutaneous delivery of insulin, at set and variable rates for the management of diabetes mellitus in persons requiring insulin.

Suitable for people living with diabetes requiring:

Icon of a group of people

Suitable For All Ages*

The Omnipod DASH® System is suitable for people living with diabetes of all ages*, lifestyles and requiring insulin.


Personalised basal and bolus insulin delivery

Personalised and flexible basal and bolus insulin delivery. An insulin delivery system that meets lifestyle and improved clinical outcomes^.

Icon - Brain

Intuitive Design

An alternative to multiple daily injections with a bolus calculator that calculates correction and meal bolus doses using individualised settings, simplifying diabetes management. Intuitive technology that is easy to learn and simple to use.

Icon - drop of water

Glucose Control

Tubeless insulin pump therapy is associated with reduced frequency of Diabetic Ketoacidosis (DKA) and severe hypoglycaemia*. Improved glycaemic control and lower total daily dose of insulin^, §.

Icon - person moving

Tangleproof Design

A tubeless option for continuous subcutaneous insulin infusion. A discreet way for your patients to manage their diabetes.

icon of a clock

No need to disconnect

No need for short-term disconnection or interruption to insulin delivery for up to 3 days.

Icon - stick-proof

Fewer Injections

On average 1 Pod provides insulin delivery for up to 3 days which would replace approximately 14 multiple daily insulin injections◊. With auto insertion cannula your patients do not see a visible needle.

◊Average number of injections required every 3 days (MDI: ~4.5 per day).

If you want to learn more or would like to speak with one of our Omnipod® Australia Representatives you can request a call below.

* Biester T. et al. Diabetes Technology and Therapeutics. 2021 DOI:
◊ ADA Position Statement, Diabetes Care 2014_2034 Pg 13 10.1089/dia.2020.0675.
^ Brown COPPER study LMC Diabetes Registry 2020 doi: 10.1111/DME.14420
§ Mehta SN et al. Clinical Diabetes Journal Clinical Diabetes 2021 Jan; 39(1): 72-79.

The Omnipod DASH® Insulin Management System is intended for subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin. The Omnipod DASH® System has been tested and found to be safe for use with the following U-100 insulin: Novolog®, Humalog®, Apidra® Fiasp® or Admelog®. Refer to the Omnipod DASH® Insulin Management System User Guide for complete safety information including indications, contraindications, warnings, cautions, and instructions.